The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: Time- and p53 expression-dependency of anti-cancer drugs

Oncology Reports

Volumn 14, Issue 3, 2005, Pages 609-615

  Matsuhashi, Nobuhisa ^a   Saio, Masanao ^a   Matsuo, Atsushi ^a   Sugiyama, Yasuyuki ^a   Saji, Shigetoyo ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

5 fluorouracil plus cisplatin treatment; Apoptosis; Multiple drug resistance; P53; Time dependent

Indexed keywords

ANTINEOPLASTIC AGENT; BISBENZIMIDE; CISPLATIN; FLUOROURACIL; PROTEIN P53;

APOPTOSIS; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; METHODOLOGY; MUTATION; PATHOLOGY; STOMACH TUMOR; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BISBENZIMIDE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; MICROSCOPY, FLUORESCENCE; MUTATION; STOMACH NEOPLASMS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 24644495281     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.3.609     Document Type: Article

References (20)

1. Greenberg B, Ahmann F, Garewal H, el al: Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. Cancer 59: 1860-1865, 1987. (Pubitemid 17072408)
2. Rougier P, Ducreux M, Mahjoubi M, et al: Efficacy of combined 5-fluorouracil and cisplatin in advanced gastric carcinomas. A phase II trial with prognostic factor. Eur J Cancer 30A: 1263-1269, 1994. (Pubitemid 24322059)
3. Kondo K, Murase M, Koreda Y, et al: Feasibility study on protracted infusinal 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 53: 64-67, 1996. (Pubitemid 26027092)
4. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H and Fukushima M: Metabolic basis of the synergistic antitumour activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Chemother Pharmacol 32: 167-172, 1993. (Pubitemid 23146807)
5. Chen XX, Lai MD, Zhang YL and Huang Q: Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. World J Gastroenterol 8: 841-846, 2002.
6. Scanlon KJ and Kashani-Sabet M: Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 85: 650-653, 1988. (Pubitemid 18073896)
7. Scanlon KJ, Kashani-Sabet M and Sowers LC: Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 4: 269-275, 1989.
8. Scanlon KJ, Funato T, Pezeshki B, Tone T and Sowers LC: Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun 2: 339-343, 1990.
9. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y and Saji S: Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 24: 807-813, 2004.
10. Kim R, Nishimoto N, Inoue H,Yoshida K, and Toge T: An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. J Infect Chemother 6: 222-228, 2000. (Pubitemid 32052316)
11. Kim R, Tanabe K, Inoue H and Toge T: Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 20: 549-555, 2002.
12. Chin KV, Ueda K, Pastan I and Gottersmann M: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-462, 1992.
13. Wang Q and Beck WT: Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58: 5762-5769, 1998. (Pubitemid 29006417)
14. Kerr JFR, Winterford CM and Harmo BV: Apoptosis: its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994. (Pubitemid 24107952)
15. Yukimoto K, Nakata B, Mugumura K, Yoshiro M, Ohira M, Ishikawa T, Hino M and Hirakawa K: Apoptosis and thymidylate synthase induction by 5-fluorouracil in gastric cancer cells with or without p53 mutation. Int J Oncol 2: 373-378, 2001.
16. Endo K, Maehara Y, Kushimoto T, Ichiyoshi Y, Kuwano M and Sugimachi K: Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 68: 372-377, 1996. (Pubitemid 26384141)
17. De Kant E, Heide I, Thieda C, Hermann R and Rochlitz CF: MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol 122: 671-675, 1996. (Pubitemid 26349020)
18. Yin F, Shi YQ, Zhao WP, Xiao B, Miao B and Fan DM: Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas. World J Gastroenterol 6: 664-670, 2000.
19. Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, Ikeda K, Tsurutani J, Ikuno N, Omagari K, Mizuta Y, Soda H, Gudas JM and Kohno S: P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 88: 738-742, 1997. (Pubitemid 27404018)
20. Galimberti S, Marchetti A, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G and Peterini M: Multidrug resistance related genes and p53 expression in human no small cell lung cancer. Anticancer Res 18: 2973-2976, 1998. (Pubitemid 28388800)